Chen Qianqian, Kong Hui, Qi Xu, Ding Wenqiu, Ji Ningfei, Wu Chaojie, Huang Chaolin, Wu Wenjuan, Huang Mao, Xie Weiping, Liu Yun, Tang Jinhai
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Division of Intensive Care Unit, Wuhan Jin Yin-tan Hospital, Wuhan, China.
Front Med (Lausanne). 2020 Oct 6;7:579543. doi: 10.3389/fmed.2020.579543. eCollection 2020.
Corona Virus Disease 2019 (COVID-19) has become a serious pandemic disease worldwide. Identification of biomarkers to predict severity and prognosis is urgently needed for early medical intervention due to high mortality of critical cases with COVID-19. This retrospective study aimed to indicate the values of carcinoembryonic antigen (CEA) in evaluating the severity and prognosis of COVID-19. We included 46 death cases from intensive care unit and 68 discharged cases from ordinary units with confirmed COVID-19 of Wuhan Jin Yin-tan Hospital from January 1 to March 22, 2020. Laboratory and radiologic data were analyzed retrospectively. All patients were followed up until April 10, 2020. COVID-19 patients in the death group had significantly higher CEA levels (ng/ml) than discharged group (14.80 ± 14.20 vs. 3.80 ± 2.43, < 0.001). The risk of COVID-19 death increased 1.317 times for each additional 1 ng/ml CEA level (OR = 1.317, 95% CI: 1.099-1.579). The standardized and weighted receiver operating characteristic curve (ROC) analysis adjusted to age, sex, and ferritin levels suggested that the area under the curve (AUC) of the serum CEA levels was 0.808 in discrimination between death cases and discharged cases with COVID-19 ( < 0.001). We found mortality of COVID-19 is associated with elevated CEA levels increased (HR = 1.023, 95% CI: 1.005-1.042), as well as age (HR = 1.050, 95% CI: 1.016-1.086) and ferritin levels (HR = 1.001, 95% CI: 1.001-1.002) by survival analysis of Cox regression model. Among discharged patients, CEA levels were significant lower in moderate cases compared to the severe and critical cases ( = 0.005; OR = 0.488, 95% CI: 0.294-0.808) from binary logistic regression analysis. The AUC of CEA levels was 0.79 in distinguishing moderate cases from discharged COVID-19 patients by standardized and weighted ROC analysis ( < 0.001). A positive correlation between CEA levels and CT scores existed in discharged patients (Correlation Coefficient: 0.687; < 0.001). Elevated CEA levels increased the risk of death from COVID-19 and CEA levels were related to CT scores of the discharged patients positively.
2019冠状病毒病(COVID-19)已成为全球范围内的严重大流行病。由于COVID-19危重症病例死亡率高,因此迫切需要鉴定生物标志物以预测病情严重程度和预后,从而进行早期医学干预。本回顾性研究旨在指出癌胚抗原(CEA)在评估COVID-19病情严重程度和预后方面的价值。我们纳入了武汉市金银潭医院2020年1月1日至3月22日确诊为COVID-19的46例重症监护病房死亡病例和68例普通病房出院病例。对实验室和影像学数据进行回顾性分析。所有患者随访至2020年4月10日。死亡组COVID-19患者的CEA水平(ng/ml)显著高于出院组(14.80±14.20 vs. 3.80±2.43,<0.001)。CEA水平每增加1 ng/ml,COVID-19死亡风险增加1.317倍(OR = 1.317,95%CI:1.099 - 1.579)。根据年龄、性别和铁蛋白水平进行调整的标准化加权受试者工作特征曲线(ROC)分析表明,血清CEA水平在区分COVID-19死亡病例和出院病例时的曲线下面积(AUC)为0.808(<0.001)。通过Cox回归模型生存分析,我们发现COVID-19死亡率与CEA水平升高相关(HR = 1.023,95%CI:1.005 - 1.042),还与年龄(HR = 1.050,95%CI:1.016 - 1.086)和铁蛋白水平(HR = 1.001,95%CI:’1.001 - 1.002)相关。在出院患者中,二元逻辑回归分析显示,中度病例的CEA水平显著低于重度和危重症病例(P = 0.005;OR = 0.488,95%CI:0.294 - 0.808)。通过标准化加权ROC分析,CEA水平在区分中度病例和COVID-19出院患者时的AUC为0.79(<0.001)。出院患者的CEA水平与CT评分呈正相关(相关系数:0.687;<0.001)。CEA水平升高增加了COVID-19死亡风险,且CEA水平与出院患者的CT评分呈正相关。